WO2005041864A3 - Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method - Google Patents

Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method Download PDF

Info

Publication number
WO2005041864A3
WO2005041864A3 PCT/US2004/034685 US2004034685W WO2005041864A3 WO 2005041864 A3 WO2005041864 A3 WO 2005041864A3 US 2004034685 W US2004034685 W US 2004034685W WO 2005041864 A3 WO2005041864 A3 WO 2005041864A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
phosphodiesterase
combination
cyclooxygenase
prevention
Prior art date
Application number
PCT/US2004/034685
Other languages
French (fr)
Other versions
WO2005041864A2 (en
Inventor
Walter G Smith
Original Assignee
Pharmacia Corp
Walter G Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Walter G Smith filed Critical Pharmacia Corp
Priority to EP04795797A priority Critical patent/EP1691797A2/en
Priority to MXPA06004499A priority patent/MXPA06004499A/en
Priority to CA002542277A priority patent/CA2542277A1/en
Priority to JP2006536743A priority patent/JP2007509154A/en
Priority to BRPI0415753-2A priority patent/BRPI0415753A/en
Publication of WO2005041864A2 publication Critical patent/WO2005041864A2/en
Publication of WO2005041864A3 publication Critical patent/WO2005041864A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

A method is described for the prevention and/or treatment of respiratory inflammation, and in particular asthma and COPD, in a subject in need of such prevention or treatment, the method comprising administering to the subject a cycloogenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor. Also described are therapeutic and pharmaceutical compositions and kits that are useful in the present invention.
PCT/US2004/034685 2003-10-21 2004-10-21 Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method WO2005041864A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04795797A EP1691797A2 (en) 2003-10-21 2004-10-21 Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
MXPA06004499A MXPA06004499A (en) 2003-10-21 2004-10-21 Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith.
CA002542277A CA2542277A1 (en) 2003-10-21 2004-10-21 Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith
JP2006536743A JP2007509154A (en) 2003-10-21 2004-10-21 Methods and compositions for the treatment or prevention of respiratory inflammation with cyclooxygenase-2 inhibitors in combination with phosphodiesterase 4 inhibitors
BRPI0415753-2A BRPI0415753A (en) 2003-10-21 2004-10-21 method for treating and preventing respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions containing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51309903P 2003-10-21 2003-10-21
US60/513,099 2003-10-21

Publications (2)

Publication Number Publication Date
WO2005041864A2 WO2005041864A2 (en) 2005-05-12
WO2005041864A3 true WO2005041864A3 (en) 2006-05-18

Family

ID=34549248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/034685 WO2005041864A2 (en) 2003-10-21 2004-10-21 Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method

Country Status (6)

Country Link
EP (1) EP1691797A2 (en)
JP (1) JP2007509154A (en)
BR (1) BRPI0415753A (en)
CA (1) CA2542277A1 (en)
MX (1) MXPA06004499A (en)
WO (1) WO2005041864A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431154B2 (en) 2002-02-20 2013-04-30 Takeda Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
US8536206B2 (en) 2003-03-08 2013-09-17 Takeda Gmbh Process for the preparation of roflumilast
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
US9265905B2 (en) 2010-06-24 2016-02-23 Ashkal Developments Limited Stopper device
US9266268B2 (en) 2002-08-14 2016-02-23 Muhammed Aslam Nasir Method of manufacturing an airway device
USD761952S1 (en) 2012-07-27 2016-07-19 Docsinnovent Limited Airway device
USD1025348S1 (en) 2020-04-16 2024-04-30 Intersurgical Ag Airway device

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536350A (en) * 2004-05-10 2007-12-13 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of roflumilast for the prevention or treatment of emphysema
CN102600144A (en) 2005-03-08 2012-07-25 奈科明有限责任公司 Roflumilast for the treatment of diabetes mellitus
JP5908884B2 (en) * 2010-03-15 2016-04-26 ヴァージニア コモンウェルス ユニヴァーシティＶｉｒｇｉｎｉａ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｕｎｉｖｅｒｓｉｔｙ Aerosolized dapsone for the treatment of airway inflammation and mucociliary transport abnormalities
GB201201438D0 (en) 2012-01-27 2012-03-14 Docsinnovent Ltd Improved stopper device
WO2013131255A1 (en) * 2012-03-07 2013-09-12 Scinopharm (Changshu) Pharmaceutical, Ltd. Preparation method of roflumilast
JP2015522528A (en) * 2012-05-09 2015-08-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Method and pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease
US9402821B2 (en) 2012-08-13 2016-08-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for treatment of cystic fibrosis
GB2521375C (en) 2013-12-17 2021-09-29 Aslam Nasir Muhammed Intubating Airway Device
USD842456S1 (en) 2015-12-15 2019-03-05 Intersurgical Ag Airway device
GB201720733D0 (en) 2017-12-13 2018-01-24 Ashkal Development Ltd Airway device
US20230017266A1 (en) * 2019-12-03 2023-01-19 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma
US20230073803A1 (en) * 2019-12-16 2023-03-09 Themis Medicare Limited Pharmaceutical composition of cyclooxygenase - 2 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20020013357A1 (en) * 1999-12-08 2002-01-31 Sreekant Nadkarni Valdecoxib compositions
US20020119193A1 (en) * 2000-08-18 2002-08-29 Le Trang T. Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
WO2003024489A2 (en) * 2001-09-19 2003-03-27 Altana Pharma Ag Combination of a nsaid and a pde-4 inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
US20020013357A1 (en) * 1999-12-08 2002-01-31 Sreekant Nadkarni Valdecoxib compositions
US20020119193A1 (en) * 2000-08-18 2002-08-29 Le Trang T. Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
WO2003024489A2 (en) * 2001-09-19 2003-03-27 Altana Pharma Ag Combination of a nsaid and a pde-4 inhibitor

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431154B2 (en) 2002-02-20 2013-04-30 Takeda Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
US9468598B2 (en) 2002-02-20 2016-10-18 Astrazeneca Ab Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US9266268B2 (en) 2002-08-14 2016-02-23 Muhammed Aslam Nasir Method of manufacturing an airway device
US9475223B2 (en) 2002-08-14 2016-10-25 Muhammed Aslam Nasir Method of manufacturing an airway device
US8536206B2 (en) 2003-03-08 2013-09-17 Takeda Gmbh Process for the preparation of roflumilast
US8618142B2 (en) 2003-03-10 2013-12-31 Takeda Gmbh Process for the preparation of roflumilast
US8604064B2 (en) 2003-03-10 2013-12-10 Takeda Gmbh Process for the preparation of roflumilast
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
US9265905B2 (en) 2010-06-24 2016-02-23 Ashkal Developments Limited Stopper device
USD768846S1 (en) 2012-01-27 2016-10-11 Ashkal Developments Limited Airway device
USD769442S1 (en) 2012-01-27 2016-10-18 Ashkal Developments Limited Airway device
USD761952S1 (en) 2012-07-27 2016-07-19 Docsinnovent Limited Airway device
USD1025348S1 (en) 2020-04-16 2024-04-30 Intersurgical Ag Airway device

Also Published As

Publication number Publication date
EP1691797A2 (en) 2006-08-23
MXPA06004499A (en) 2006-06-27
WO2005041864A2 (en) 2005-05-12
JP2007509154A (en) 2007-04-12
BRPI0415753A (en) 2006-12-19
CA2542277A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
WO2005041864A3 (en) Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
WO2003000241A3 (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents, for the treatment of inflammatory and/or obstructive respiratory tract diseases
WO2002069945A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
WO2005009342A3 (en) Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2005055932A3 (en) Therapeutic combinations and methods including irm compounds
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2004009558A3 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
WO2004017948A8 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2004047792A3 (en) Liposomal glucocorticoids
WO2005023189A3 (en) Method of cox-2 selective inhibitor and nitric oxide-donating agent
WO2003087049A3 (en) Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
WO2004028548A3 (en) Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents
IL168308A (en) Compositions containing roflumilast and formoterol
WO2004094373A3 (en) A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
MXPA03011702A (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases.
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
EP1336619A3 (en) Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
WO2005020926A3 (en) Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
WO2005123113A3 (en) Interferon compositions and methods of use thereof
WO2004093813A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
WO2003084503A3 (en) P38 kinase inhibitors for treating mucus hypersecretion_
WO2005009340A3 (en) Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2542277

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006536743

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/004499

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004795797

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004795797

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004795797

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0415753

Country of ref document: BR